Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

With the best LED face masks now repping technology ... “Red light is an anti-ageing treatment used to promote collagen production and to enhance skin elasticity,” Dr Nyla explains, while ...

For those with chronic conditions, such as COPD, a healthcare professional will work with the individual to help them breathe more easily. This will involve developing a treatment plan that helps ...

The best CBD tinctures are portable, easy-to-dose options that offer an alternative treatment for conditions from chronic pain to anxiety. These top picks are effective, high quality, and ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

To help with COPD flare-ups, you may consider a medication inhaler, antibiotics, oxygen therapy, and hospital care. Your healthcare team can best advise you on treatment for COPD exacerbations.

The study included a 6-week screening period, 52 weeks of treatment, and a 12-week safety follow-up. The annualized rate of moderate or severe COPD exacerbations for 52 weeks was the primary endpoint.